While there are approved drugs for chronic liver diseases, they have limited success treating fibrosis, their underlying cause. This deficiency suggests that current liver fibrosis models are inadequate and require improvement for more accurate disease recapitulation and predictive drug testing.
To address this gap in liver disease treatment and beyond, scientists are developing better in vitro disease models with decellularized extracellular matrix (dECM) coatings and hydrogels derived from primary tissues. These dECMs provide cells with tissue-specific biochemical signals that are missing in other in vitro systems, recreating a native cellular environment for both 2D and 3D cultures.
In this webinar, brought to you by Xylyx, research scientist Andrew Schmidt will discuss his research using liver models made with physiologically relevant dECM that can deliver more predictive results compared to conventional cell culture.
Topics to be covered in this webinar
- Why current liver fibrosis models fall short in predicting drug efficacy
- How decellularized extracellular matrix (dECM) coatings and hydrogels from primary tissues restore tissue-specific biochemical cues missing from conventional in vitro systems
- How physiologically relevant liver models can generate more predictive results than standard cell culture